Palladium Partners’s Abiomed Inc ABMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
$490K Hold
1,478
0.02% 245
2021
Q4
$531K Buy
1,478
+800
+118% +$270K 0.02% 240
2021
Q3
$221K Sell
678
-27
-4% -$9.15K 0.01% 273
2021
Q2
$220K Sell
705
-23
-3% -$7.06K 0.01% 266
2021
Q1
$232K Hold
728
0.01% 263
2020
Q4
$236K Hold
728
0.01% 238
2020
Q3
$202K Sell
728
-197
-21% -$56.8K 0.01% 238
2020
Q2
$223K Buy
+925
New +$186K 0.02% 232
2019
Q4
Sell
-1,390
Closed -$625K 282
2019
Q3
$625K Buy
1,390
+165
+13% +$35.7K 0.04% 179
2019
Q2
$319K Sell
1,225
-50
-4% -$13.3K 0.02% 219
2019
Q1
$364K Sell
1,275
-100
-7% -$33.2K 0.03% 208
2018
Q4
$447K Sell
1,375
-15
-1% -$5.21K 0.04% 194
2018
Q3
$625K Sell
1,390
-125
-8% -$49.3K 0.04% 186
2018
Q2
$620K Sell
1,515
-650
-30% -$235K 0.05% 183
2018
Q1
$630K Buy
2,165
+650
+43% +$165K 0.05% 179
2017
Q4
$284K Sell
1,515
-174
-10% -$32.5K 0.02% 235
2017
Q3
$285K Hold
1,689
0.02% 227
2017
Q2
$242K Hold
1,689
0.02% 235
2017
Q1
$211K Buy
+1,689
New +$196K 0.02% 246
2016
Q4
Sell
-1,689
Closed -$217K 252
2016
Q3
$217K Buy
+1,689
New +$202K 0.02% 240

Other funds holding ABMD

Palladium Partners's ABMD Position: Q1 2022 in Review

Palladium Partners held its Abiomed Inc (ABMD) position steady in Q1 2022 at 1,478 shares worth $490K. The position accounts for 0.02% of the portfolio, ranked #245.

Palladium Partners first reported a position in ABMD in Q3 2016 and has held it in 20 quarters since. The position peaked at $630K in Q1 2018. 500 funds tracked by Wall St. Rank hold ABMD as of Q1 2022.

  • Palladium Partners held 1,478 shares of Abiomed Inc worth $490K as of Q1 2022.
  • Palladium Partners left its Abiomed Inc share count unchanged in Q1 2022.
  • Abiomed Inc made up 0.02% of Palladium Partners's portfolio in Q1 2022, its #245 holding.
  • Palladium Partners first reported a position in Abiomed Inc in Q3 2016 and has held it in 20 quarters since.
  • Palladium Partners's Abiomed Inc position peaked at $630K in Q1 2018.
  • 500 funds tracked by Wall St. Rank held Abiomed Inc as of Q1 2022.

Based on Palladium Partners's 13F filing for Q1 2022, filed 26 Apr 2022.